Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alavert Sales Up 48% As Wyeth Stands Strong In Crowded Loratadine Market

This article was originally published in The Tan Sheet

Executive Summary

Wyeth is confident that its Alavert loratadine product will weather the launch of several private label and generic rivals and build on the brand's strong second quarter sales performance

You may also be interested in...



Impax loratadine approval

Hayward, Calif.-based firm's ANDA for loratadine/pseudoephedrine sulfate 10 mg/240 mg (equivalent to Schering-Plough's Claritin D-24) was approved by FDA, Impax announces March 5. The firm already is authorized to manufacture equivalents to Claritin D-12 and the orally disintegrating Claritin Reditabs. Impax will supply the D-24 equivalent to Wyeth Consumer Healthcare for marketing, mostly likely under the Alavert brand. Wyeth has announced plans for a "complete range" of loratadine products in the Alavert line (1"The Tan Sheet" July 28, 2003, p. 11)...

Impax loratadine approval

Hayward, Calif.-based firm's ANDA for loratadine/pseudoephedrine sulfate 10 mg/240 mg (equivalent to Schering-Plough's Claritin D-24) was approved by FDA, Impax announces March 5. The firm already is authorized to manufacture equivalents to Claritin D-12 and the orally disintegrating Claritin Reditabs. Impax will supply the D-24 equivalent to Wyeth Consumer Healthcare for marketing, mostly likely under the Alavert brand. Wyeth has announced plans for a "complete range" of loratadine products in the Alavert line (1"The Tan Sheet" July 28, 2003, p. 11)...

Impax loratadine approval

Hayward, Calif.-based firm's ANDA for loratadine/pseudoephedrine sulfate 10 mg/240 mg (equivalent to Schering-Plough's Claritin D-24) was approved by FDA, Impax announces March 5. The firm already is authorized to manufacture equivalents to Claritin D-12 and the orally disintegrating Claritin Reditabs. Impax will supply the D-24 equivalent to Wyeth Consumer Healthcare for marketing, mostly likely under the Alavert brand. Wyeth has announced plans for a "complete range" of loratadine products in the Alavert line (1"The Tan Sheet" July 28, 2003, p. 11)...

Related Content

Topics

UsernamePublicRestriction

Register

PS095727

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel